Savant Capital LLC Has $256,000 Stake in Medpace Holdings, Inc. $MEDP

Posted by Francis Steltz on Jun 7th, 2026

Savant Capital LLC trimmed its stake in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 95.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 455 shares of the company’s stock after selling 9,721 shares during the period. Savant Capital LLC’s holdings in Medpace were worth $256,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. Foundations Investment Advisors LLC bought a new position in shares of Medpace in the 4th quarter valued at approximately $472,000. Geode Capital Management LLC raised its stake in shares of Medpace by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after acquiring an additional 24,625 shares in the last quarter. King Luther Capital Management Corp raised its stake in shares of Medpace by 4.2% in the 4th quarter. King Luther Capital Management Corp now owns 18,331 shares of the company’s stock valued at $10,296,000 after acquiring an additional 739 shares in the last quarter. Jackson Creek Investment Advisors LLC bought a new position in shares of Medpace in the 4th quarter valued at approximately $1,286,000. Finally, Fisher Asset Management LLC raised its stake in shares of Medpace by 0.8% in the 4th quarter. Fisher Asset Management LLC now owns 138,799 shares of the company’s stock valued at $77,957,000 after acquiring an additional 1,053 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

Medpace News Summary

Here are the key news stories impacting Medpace this week:

Negative Sentiment: Multiple law firms, including Rosen, Pomerantz, Schall, Faruqi & Faruqi, and others, reiterated that a class action has been filed against Medpace alleging violations of federal securities laws and investor harm. Article Title
Negative Sentiment: The lawsuits center on purchases made between April 22, 2025 and February 9, 2026, with investors urged to act before the June 8 lead-plaintiff deadline, keeping legal risk and uncertainty in focus. Article Title
Neutral Sentiment: One item noted a management change, with Medpace elevating Brad Hansman to an executive operations role, but this appears to be a routine corporate update with no immediate market-moving detail. Article Title

Medpace Trading Down 1.0%

MEDP opened at $454.25 on Friday. The stock has a market cap of $12.97 billion, a PE ratio of 28.55, a P/E/G ratio of 2.30 and a beta of 1.18. Medpace Holdings, Inc. has a 1 year low of $294.07 and a 1 year high of $628.92. The stock’s 50 day simple moving average is $456.73 and its 200-day simple moving average is $508.93.

Medpace (NASDAQ:MEDP – Get Free Report) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. The business had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.Medpace’s quarterly revenue was up 26.5% on a year-over-year basis. During the same period in the previous year, the business posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts forecast that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on MEDP shares. Truist Financial cut their price objective on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research note on Wednesday, February 11th. Mizuho set a $582.00 price objective on Medpace in a research note on Wednesday, February 11th. Weiss Ratings downgraded Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. BMO Capital Markets cut their price objective on Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research note on Friday, April 24th. Finally, Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a research report on Friday, February 13th. Four equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Medpace currently has a consensus rating of “Hold” and a consensus price target of $467.08.

Read Our Latest Report on MEDP

Insider Buying and Selling

In other news, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the sale, the president directly owned 15,000 shares in the company, valued at approximately $6,829,500. The trade was a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 20.50% of the company’s stock.

Medpace Profile

(Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.